Head of Droplet-based Microfluidics Applications - Associate Director

The role

The Associate Director will lead the development and expansion of applications for the droplet-based microfluidics platform. This person will manage engineering staff and drive solutions to better understand functional biology.

What you will do

• Lead the further development of the droplet-based microfluidics platform and its applications.
• Assess problems that can be addressed with the platform by talking with the biology team.
• Define projects and timelines to develop applications to better understand functional biology.
• Drive and execute projects to ensure delivery of results within set timelines.
• Mentor junior engineers to develop them into mature professionals.
• Promote a culture of collaboration, innovation, and deep scientific rigor.

Required qualifications

• Ph.D. in an engineering or physical science field
• Expertise in droplet-based functional biology applications supported by publications in peer-reviewed journals
• Hands-on experience in designing droplet-based microfluidic chips, manufacturing microfluidic chips, and designing and executing droplet-based biological assays
• Experience working on the whole process end-to-end
• Experience across disciplinary boundaries and working in a multi-disciplinary team
• 3+ years of leadership experience in industry
• Experience managing a team, leading projects and delivering results within defined timelines
• Ability to present clearly and concisely to the executive team and external stakeholders

Nice to have

• Electric Engineering, Physics, Applied Physics, Bioengineering, Biotechnology, Mechanical engineering or Chemical Engineering

Benefits

• Daily lunches
• Commuter Benefits
• Unlimited snacks and drinks
• Medical, Dental, Vision; 100% Premium Covered
• Disability Insurance
• Life Insurance
• Workplace Insurance
• Flexible time-off policy
• Mentorship
• Growth opportunities
• Merit-based promotions

About the company

Shennon Biotechnologies is developing precision immunotherapies for solid tumors through an integrated technology platform. They are based in the dogpatch neighborhood of San Francisco.